A growing number of women with chronic inflammatory diseases are continuing to use TNF inhibitors throughout pregnancy.

Overall, 503 patients received first-line TNF inhibitors, of whom 261 switched to upadacitinib, while 128 switched to another TNF inhibitor and 114 switched to another mechanism of action.

But for those kids, anti-TNF drugs decreased their risk of anal fistulas by 93%, researchers found. Anti-TNF drugs are pricier than other anti-inflammatory drugs used to treat Crohn's like ...

Tapering TNF inhibitors is safe and maintains low disease activity for 2 years in psoriatic arthritis and axial ...

In moderate to severe Crohn's disease, a network meta-analysis suggested that TNF inhibitor-based therapy was the most ...

Juvenile idiopathic arthritis, older age, and concomitant immunomodulation delay the onset of psoriasiform dermatitis in ...

Observational data in inflammatory bowel disease (IBD) supported the safety of JAK inhibitors versus TNF inhibitors in terms of serious outcomes -- including blood clots, major heart events, and ...

Tumor necrosis factor inhibitor use in patients with IMIDs did not increase the risk of de novo heart failure or worsen existing heart failure.

As second-line therapy for PsA and axSpA, no clear treatment-retention benefit at 3 years was seen when swapping to a bDMARD with another MOA.

However, that same analysis in JAMA Network Open found that use of TNF inhibitors was ultimately not associated with a higher risk for all-cause mortality (aHR 1.02, 95% CI 0.86-1.21).

The incidence rate for cardiovascular events among patients exposed to TNF inhibitors was 8.92/10,000 person-years, 12.87/10,000 person-years for IL-17 inhibitor exposure, and 18.66/10,000 person ...

A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic ...